Navigation Links
Top scientists meet for global conference on stem cell therapy for cardiovascular diseases
Date:12/19/2007

WHAT:

The Cardiovascular Research Foundation (CRF) brings experts to New York City from around the world for the Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases. Dedicated to new advances in this emerging field, the three-day session will feature an in-depth review of cell-based therapies for myocardial repair and regeneration, angiogenesis and cutting-edge research findings.

Highlights include:

  • Clinical Focus: Full-day programs for the discussion of heart attacks (ST elevation myocardial infarction, or STEMI) and congestive heart failure (CHF). Each will cover strategies using cell-based therapies to address the chronic ventricular dysfunction underlying these conditions.

  • Cutting Edge Findings including:

    • Work by Dr. Marc Penn and colleagues demonstrating that bone marrow cells can improve heart function soon after a heart attack by saving heart cells that would otherwise die from the attack

    • Research performed by Dr. Gordon M. Keller and colleagues showing for the first time how human embryonic stem cells can be induced into becoming human heart muscle cells, raising new potential for regenerating cardiac muscle after a heart attack

    • First-ever results of work by Dr. A. Terzic and colleagues demonstrating how bone marrow cells can be stimulated into essentially becoming heart muscle cells, something which in recent years had not been thought possible

    • Dr Keith March will present new data showing that 2 special types of cells are necessary to grow new blood vessels, opening up an exciting strategy for the next round of clinical trials

  • Special Sessions on:

    • Cardiac Tissue Engineering, including exciting work in constructing blood vessels and cell sheets of myocardial tissue

    • Angiogenesis, including the use of stem cells derived from bone marrow, adipose, and other sources to synthesize functioning myocardium in patients with heart and peripheral vascular disease

  • Late Breaking Clinical Trials:

    • Long-term results from two major trials (TOPCARE, REPAIR-AMI) of bone-marrow- or blood-derived progenitor cells for acute myocardial infarction will be reviewed by Dr. Andreas M. Zeiher

    • Intravenous allogeneic mesenchymal stem cells for acute myocardial infarction will be presented by Dr. Joshua M. Hare

    • MAGIC 5: combined approach using granulocyte colony stimulating factor (G-CSF), erythropoietin mobilization, and intracoronary cell infusion in patients with heart attack, presented in detail here by Dr. Hyo-Soo Kim

    • Data presented by Dr. Hans Dohmann will demonstrate the primary mechanism by which bone marrow cells help patients with acute myocardial infarction

    • Bone marrow-derived stem cells for patients with critical limb ischemia, presented by both Drs. Berthold Amann and Brian Annex

    • Transplantation of bone marrow stem cells for persistent, refractory angina, presented and discussed by Drs. Douglas Losordo and Jorge Tuma

    • CausMic: A randomized, controlled study of myoblasts in patients with heart failure, first reported at AHA 2007, presented in detail here by Dr. Nabil Dib

    • Final 12 month data from the MYOHEART trial in patients with heart failure will be presented for the first time by Dr. Warren Sherman

    • Stem cells in patients with heart failure on left ventricular assist devices, presented by Dr. Eric A. Rose

  • Next-Generation Heart Muscle Cells: Advances in skeletal, myocardial, embryonic, and bone marrow derived techniques

  • A Preview of First-in-Human Studies Planned for the Coming Year

  • MARVEL: the largest randomized placebo-controlled study of skeletal myoblasts in patients with heart failure, presented by Dr. Warren Sherman

  • PRIMO-AMI; a novel bone-marrow derived cell and injection technique in patients with heart attack, presented by Dr. Marc Penn

  • Views of the Future: The last session will 1) present scientific collaborations that will play a major role in stem cell studies, and, 2) offer an extraordinary opportunity for leaders of the field to present their views on future clinical benefits in an open, round-table discussion

WHO:

Hundreds of the worlds leading cell therapy experts will meet to discuss the latest advances in this area.

Warren Sherman, M.D., Conference Director, is Director of Cardiac Cell-Based Endovascular Therapies at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital and Columbia University Medical Center. Dr. Sherman is a renowned clinical investigator in the field of myocardial regeneration who pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of stem cells into the heart of a patient with congestive heart failure due to a previous heart attack. At Columbia University Medical Center, researchers led by Dr. Sherman are using the patients own myoblasts -- progenitor cells found in muscle -- to repair and replace injured cardiac tissue in a process called myogenesis. Dr. Sherman collaborates in studies to improve the outcomes of cell implantation with colleagues at Columbia University Medical Center, all of whom will be presenting their research at the conference.

WHEN:
January 16 18, 2008

WHERE:
Columbia University, Alfred Lerner Hall, 2920 Broadway (at 115th St.), New York, NY


'/>"/>

Contact: Claire Laporte
claporte@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related biology news :

1. UK scientists working to help cut ID theft
2. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
3. Comet probes reveal evidence of origin of life, scientists claim
4. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
5. Male elephants get photo IDs from scientists
6. Scientists retrace evolution with first atomic structure of an ancient protein
7. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
8. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
9. Clemson scientists shed light on molecules in living cells
10. Scientists tackle mystery mountain illness
11. T. rex quicker than Becks, say scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 31, 2015. --> --> ... percent compared to the comparable quarter last year to $470.5 million. ... million, or $0.93 per diluted share. --> ... of fiscal 2016 grew 9 percent over the prior year period ...
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today that Edward Lanphier , Sangamo,s president and ... progress of Sangamo,s ZFP Therapeutic ® development programs ... 2:40 pm ET on Thursday, February 11, 2016, at ... Conference. The conference is being held in ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
(Date:2/4/2016)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today provided an update on the Company,s ... of Texas and announcing that ... Partes Re-examination ("IPR") proceedings that VTech and Uniden ... initiated on only certain claims of two of the ...
(Date:2/4/2016)... ... ... Many of the engineers at FireflySci, Inc. have been manufacturing quartz and ... other cuvette manufacturers is their supercharged customer service and their extensive database of glass ... flow of inside information, they have recently revamped their manufacturing techniques to reduce lead ...
Breaking Biology Technology: